Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (1153)	10/28/1998 8:51:00 AM
From: Todd N. Weisrock	Read Replies (1) \| Respond to of 1432

BIOTIME late Monday rebutted allegations that it had made false statements about how fast regulators would review the status of the biotech firm's blood substitute product Hextend. The company, responding to allegations from short-seller Asensio & Co. that it had mislead investors into believing Hextend was being given a priority review by the FDA, said it had never told investors the product was being given an expedited review. Biotime President Ronald Barkin said he expected regulators to complete their review of Hextend in six to 18 months from its April 1 filing of a new drug application. (Reuters 07:26 PM ET 10/26/98) For the full text story, see infobeat.com